B Escudier1. Show Affiliations » 1. Institut Gustave Roussy, Villejuif, France.
Abstract
Entities: Chemical Disease
Mesh： See more » Antineoplastic Agents/adverse effectsAntineoplastic Agents/therapeutic useBenzenesulfonates/therapeutic useCarcinoma, Renal Cell/drug therapyCarcinoma, Renal Cell/metabolismCarcinoma, Renal Cell/pathologyClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicDrug Therapy, CombinationHumansInterferons/therapeutic useKidney Neoplasms/drug therapyKidney Neoplasms/metabolismKidney Neoplasms/pathologyNiacinamide/analogs & derivativesPhenylurea CompoundsProtein Kinase Inhibitors/adverse effectsProtein Kinase Inhibitors/therapeutic usePyridines/therapeutic useRandomized Controlled Trials as TopicSorafenibTreatment Outcome
Substances： See more » Antineoplastic AgentsBenzenesulfonatesPhenylurea CompoundsProtein Kinase InhibitorsPyridinesNiacinamideInterferonsSorafenib
Year: 2007 PMID： 17631603 DOI： 10.1093/annonc/mdm301
Source DB: PubMed Journal: Ann Oncol ISSN： 0923-7534 Impact factor: 32.976